Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis

The aim of this study was to evaluate c-erbB-2 overexpression by means of a quantitative biochemical technique in 488 primary breast cancer patients w ith long-term follow-up (median, 10 years) and its relation to other bioche mical prognostic factors (uPA, p53, and epidermal growth factor receptor) a nd adjuvant therapy. High levels of c-erbB-2 (>500 IU/mg protein) were associated with estrogen receptor (ER) and progesterone receptor negativity, high histoprognostic SB R grade and high levels of uPA and p53, Univariate analyses showed shorter metastasis-free survival (MFS) and overall survival (OS) in patients whose tumors overexpressed c-erbB-2 in the overall population, in subgroups defin ed by ER and uPA status, and in patients with positive pathological nodal s tatus, SBR grade II, progesterone receptor, and p53-negative tumors. Patien ts with ER-positive, c-erbB-2-positive tumors had a shorter MFS and OS than those patients with c-erbB-2-negative tumors. No difference was observed b etween adjuvant-treated and untreated patients (chemotherapy and/or hormone therapy) in the c-ErbB-2-negative subgroup. There was a trend toward a lon ger short-term MFS in c-erbB-2-positive patients treated with chemotherapy, whereas an opposite effect was observed with hormone therapy. Cox multivariate analyses showed that high levels of c-erbB-2 negatively in fluenced MFS in the overall population as well as In node-positive patients and in tamoxifen-treated patients, along with pN and uPA. Results for OS w ere comparable with those obtained for MFS, These results suggest that c-er bB-2 overexpression in breast cancer may be a better predictor of the respo nse to tamoxifen than is ER status alone.